HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nanotech bill sails through House

This article was originally published in The Rose Sheet

Executive Summary

The House passes H.R. 554 Feb. 11 to direct federal nanotechnology research, strengthen public-private partnerships through industry liaison groups and prioritize public health and safety. An identical version of the National Nanotechnology Initiative Amendments Act cleared the House in 2008, but failed in the Senate (1"The Rose Sheet" Jan. 26, 2009, p. 6). In a same-day release, bill sponsor and Science and Technology Committee Chairman Bart Gordon says the legislation "will reduce the current uncertainty that inhibits commercial development of nanotechnology and will provide a sound basis for future rulemaking." The Tennessee Democrat adds that nanotechnology could be a $2.6 trillion industry by 2014

You may also be interested in...



Rep. Gordon retiring

House Committee on Science and Technology Chairman Bart Gordon, a sponsor of legislation to promote nanotechnology, announced Dec. 14 he will not seek re-election in 2010 and will resign at the end of the 111 Congress. The Tennessee Democrat sponsored the National Nanotechnology Initiative Amendments Act - which passed the House in February - to direct federal nanotechnology research, including prioritizing public health protection (1"The Rose Sheet" Feb. 16, 2009)

Marketplace In Brief

CFSAN on nanotech: FDA's Center for Food Safety and Applied Nutrition continues to seek information from industry on nanotechnology in products including cosmetics and dietary supplements, and has no plans for now to move forward with separate regulations or a definition for products derived through nano-engineering, senior FDA staff including Office of Cosmetics and Colors Director Linda Katz reported in February during the Food and Drug Law Institute's annual meeting in Washington D.C. Regulation will continue to be driven by statutory classification, the center added, noting it has no plans to update the 2007 Nanotechnology Task Force Report. The House passed H.R. 554 on Feb. 11 in an effort to direct federal nanotech research, strengthen public-private partnerships and prioritize public health and safety (1"The Rose Sheet" Feb. 16, 2009, In Brief)

House Kicks Off New Year With Bill To Sharpen Federal Nanotech Plan

The House Committee on Science and Technology will consider legislation crafted to provide strategic direction to the federal research program for nanotechnology

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015967

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel